Search Results
Your search for The ASCO matches 21112 pages
Showing 5551 - 56002021 Genitourinary Cancers Symposium: Advancements in the Care of Older Adults With Prostate Cancer
The 2021 Genitourinary (GU) Cancers Symposium was held in a virtual format on February 11–13 and featured the latest developments in the understanding and treatment of genitourinary cancers. The impact of prostate cancer therapies on outcomes in older adults continues to be a growing area of...
Douglas R. Lowy, MD, FAACR, Honored With 2021 AACR–Margaret Foti Award
The American Association for Cancer Research (AACR) presented Douglas R. Lowy, MD, FAACR, with the 2021 AACR–Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the virtual AACR Annual Meeting 2021. Dr. Lowy is Chief of the Laboratory of Cellular Oncology,...
FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic EGFR Exon 20 Insertion–Mutated NSCLC
On May 21, the U.S. Food and Drug Administration (FDA) granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor and MET receptors, for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and...
AACR Announces Recipients of 2021 Scientific Achievement Awards and Lectureships
The American Association for Cancer Research (AACR) honored a number of cancer researchers, physician-scientists, advocates, and policymakers for their achievements during week 1 of the virtual AACR Annual Meeting 2021 (April 10–15, 2021). Several of these recipients were mentioned in previous...
AACR to Recognize the St. Baldrick’s Foundation–SU2C Pediatric Cancer Dream Team With 2021 Team Science Award
The American Association for Cancer Research (AACR) will recognize the St. Baldrick’s Foundation–Stand Up To Cancer (SU2C) Pediatric Cancer Dream Team with the 2021 AACR Team Science Award. In early 2013, the St. Baldrick’s Foundation and SU2C collaborated to create a Pediatric Cancer Dream Team...
Lisa M. Coussens, PhD, FAACR, Elected AACR President-Elect for 2021–2022
The members of the American Association for Cancer Research (AACR) have elected Lisa M. Coussens, PhD, FAACR, as their President-Elect for 2021–2022. She started her official role as President-Elect on April 12, 2021, during the AACR’s Business Meeting of Members and will assume the Presidency in...
New President and Executive Council Officers for the Society of Surgical Oncology
The Society ofSurgical Oncology (SSO) recently announced its 2021–2022 elected Executive Council Officers, including its new President, Douglas S. Tyler, MD, MSHCT, FSSO. Dr. Tyler currently holds the John Woods Harris Distinguished Chair in Surgery at The University of Texas Medical Branch in...
2021 ASCO Annual Meeting: Data From a Premeeting Presscast
The 2021 ASCO Annual Meeting kicked off this week with a premeeting presscast, where data from five studies to be presented at the conference were discussed. On this podcast, we’ll hear from two authors featured in that presscast about findings in non–small cell lung cancer and the effect of...
FDA Pipeline: Applications Accepted for Marginal Zone Lymphoma and Lung Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to zanubrutinib in pretreated patients with marginal zone lymphoma, and accepted a biologics license application for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line...
Avapritinib vs Other Tyrosine Kinase Inhibitors for PDGFRA D842V–Mutated Gastrointestinal Stromal Tumors
Data from a study published by Margaret von Mehren, MD, and colleagues in BMC Cancer showed that avapritinib, a platelet-derived growth factor receptor A (PDGFRA) inhibitor, has a “clinically meaningful benefit” for the treatment of gastrointestinal stromal tumors (GIST) with PDGFRA D842V...
Equitable Cancer Care: Steps Toward Meaningful Change
As President-Elect of ASCO, you are asked to choose a theme for your presidency. This can be a daunting task, as the theme will not only shape the discourse of your presidency, but also, more importantly, that of the Society. The subject should be one that reflects the needs of the cancer community ...
ASCO’s President-Elect Focuses on Advancing Equitable Cancer Care Through Innovation
Internationally renowned for his pioneering research in combining high-dose radiation therapy and chemotherapy in the treatment of locally advanced head and neck cancer to improve patient survival, ASCO’s President-Elect Everett E. Vokes, MD, FASCO, is dedicating his tenure as President to...
FDA Approves Nivolumab for Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy. CheckMate 577 Efficacy was evaluated in CheckMate ...
American Cancer Society Releases Report on Cancer Prevention and Screening
An American Cancer Society (ACS) review of cancer prevention and early detection measures for 2018 and 2019 in the United States shows mixed progress. Smoking prevalence during this time was at an historic low, partly because most people who ever smoked have quit. However, obesity rates remained...
Standard Multigene Testing Could Detect More Hereditary Cancer Syndromes in Patients With Colorectal Cancer
Up to 38.6% of people with colon cancer who have a hereditary cancer syndrome—including 6.3% of those with Lynch syndrome—could have their conditions remain undetected with current universal tumor-screening methods, and at least 7.1% of people with colorectal cancer have an identifiable inherited...
Heather A. Wakelee, MD, on NSCLC: Atezolizumab vs Best Supportive Care After Chemotherapy
Heather A. Wakelee, MD, of Stanford University Medical Center, discusses the primary disease-free survival results of IMpower010, a phase III study that compared adjuvant atezolizumab vs best supportive care after adjuvant chemotherapy in patients with early-stage resected non–small cell lung...
Jingxuan Zhao, MPH, on How Medicaid Expansion Affects Long-Term Cancer Survival
Jingxuan Zhao, MPH, of the American Cancer Society, discusses study findings that showed worse long-term survival among low-income patients with cancer who live in states that have not expanded Medicaid eligibility (Abstract 6512).
First-Line Nivolumab/Relatlimab vs Nivolumab Alone for Advanced Melanoma
Treatment with the anti–PD-1 therapy nivolumab plus the LAG-3–blocking antibody relatlimab extended time to disease progression for patients with previously untreated, unresectable, or metastatic melanoma. Findings from the RELATIVITY-047 trial were presented by Evan J. Lipson, MD, and colleagues...
Increased PSA Screening Linked to Lower Risk of Advanced Prostate Cancer at Diagnosis and Death From the Disease in Younger Black Patients
Younger Black men undergoing frequent prostate-specific antigen (PSA) screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study by Qiao et al presented at a presscast in advance of the 2021...
Does Adjuvant Atezolizumab Extend Disease-Free Survival in Patients With Resected Early-Stage NSCLC?
Patients with resected early-stage non–small cell lung cancer (NSCLC) who received the PD-L1 inhibitor atezolizumab following cisplatin-based chemotherapy had a 34% reduction in the risk of disease recurrence compared with best supportive care, according to the results from the phase III IMpower010 ...
Study Finds Income Eligibility Limits for Medicaid May Be Associated With Worse Long-Term Survival Among Newly Diagnosed Patients With Cancer
A study investigating the association between state Medicaid income eligibility limits and long-term survival among newly diagnosed patients with cancer has found that patients living in states with lower Medicaid income eligibility limits had worse long-term survival compared with patients living...
With the Exception of Cervical Cancer, HPV-Related Cancers Are on the Rise, Especially in Older Adults
Although the incidence of cervical cancer has decreased by 1.03% a year over the last 16 years—likely due to screening or human papillomavirus (HPV) vaccination—other HPV-related cancers are increasing in both men and women, according to a study by Liao et al presented at a presscast in advance of...
USPSTF Issues New Recommendation Statement on Colorectal Cancer Screening
Prompted by a rise in cases of colorectal cancer in people younger than 50, the U.S. Preventive Services Task Force (USPSTF) has recommended that individuals at average risk for the disease begin screening exams at age 45 instead of the traditional age of 50. The guideline changes, published in...
Risk of Second Cancer by Hormone Receptor Status Among Breast Cancer Survivors
A new study has found breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, published by Hyuna Sung, PhD, and colleagues in the journal Cancer, stated that compared to the general population in the United States, the risk of new...
Report Shows Medicaid Expansion Alone Does Not Resolve Disparities in Cancer Care
In the United States, Black and Latinx individuals have higher cancer mortality rates than patients of other races. Under the Patient Protection and Affordable Care Act (ACA) in 2014, many states expanded Medicaid eligibility, promising significant gains in coverage for racial minorities. But it...
TLR4 as a Possible Therapeutic Target to Mitigate Cisplatin-Induced Hearing Loss
A research team has identified a receptor in cells that could play a role in preventing permanent hearing loss in childhood cancer survivors treated with the drug cisplatin. The researchers believe that by inhibiting the receptor, they may be able to better control otoxicity, according to findings...
Mutational Profile of Acral Nevi May Differ From Acral Melanoma
Melanocytic nevi are nonmalignant growths that arise from pigment-producing cells of the skin. They are mostly found in sun-exposed areas; however, they also can be found in sun-protected areas, such as the palms, soles of the feet, and nail beds, where they are known as acral nevi. While the...
Abemaciclib-Associated Adverse Events: Safety Analysis of monarchE
Treatment with abemaciclib, an orally available inhibitor of CDK4/6, has been associated with venous thromboembolic events (VTE), elevated aminotransferases (EAT), and interstitial lung disease (ILD). Although more episodes of VTE, EAT, and ILD were reported in patients receiving abemaciclib plus...
Long-Term Follow-up of Premenopausal Patients With Estrogen Receptor–Positive Breast Cancer: Goserelin and Tamoxifen
A 20-year follow-up of premenopausal patients with estrogen receptor–positive breast cancer and stratification by the molecular 70-gene risk signature suggested that patients at high risk of distant disease recurrence derive significant benefit from goserelin, while patients at low risk have...
ACMG Clinical Practice Resource Provides New Guidance for Management of Individuals With PALB2 Gene Variants
The American College of Medical Genetics and Genomics (ACMG) has released a clinical practice resource from a global team of specialists in cancer genetics that will help inform the clinical management of patients who harbor a PALB2 variant and may be at increased risk of developing breast,...
Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer
Drug-related interstitial lung disease occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan-nxki (T-DXd) at the approved dose of 5.4 mg/kg. In addition, the majority of these cases were classified as grade 1 or 2,...
Atezolizumab/Carboplatin as Immune Induction in Patients With Metastatic Invasive Lobular Breast Cancer
First results from the phase II GELATO study evaluating atezolizumab plus carboplatin presented at the ESMO Breast Cancer Virtual Congress 2021 demonstrated clinical benefit in patients with metastatic invasive lobular breast cancer, particularly in patients with triple-negative invasive lobular...
Biomarker Analysis of the KAITLIN Trial: No Subgroup Benefits More From T-DM1 Plus Chemotherapy
In the phase III KAITLIN trial, replacing adjuvant taxane and trastuzumab with ado-trastuzumab emtansine (T-DM1) did not result in a significant improvement in invasive disease-free survival in the node-positive or intent-to-treat population, as reported by Harbeck et al at the 2020 ASCO Virtual...
FDA Pipeline: Priority Reviews in Kidney and Endometrial Cancers, Cholangiocarcinoma
Recently, the U.S. Food and Drug Administration (FDA) has granted Priority Review to the combination of pembrolizumab and lenvatinib for the treatment of both advanced renal cell carcinoma (RCC) and endometrial carcinoma. The FDA also granted Priority Review to ivosidenib for the treatment of...
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics
The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors. This research was presented by...
Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated
PRESERVE 4 (ClinicalTrials.gov identifier: NCT04863248)—a multicenter, randomized, double-blind, placebo-controlled phase II study of trilaciclib administered prior to docetaxel in patients with metastatic non–small cell lung cancer (NSCLC) in the second- and third-line setting who have previously...
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents
On May 10, the U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to include adolescents aged 12 through 15. The FDA...
How MRD Assessment May Help Guide Treatment Selection for Patients With AML
Complete morphologic remission is considered the first requirement for achieving long-term, leukemia-free survival and a potential cure in patients with acute leukemia, including acute myeloid leukemia (AML), and is the goal of all therapeutic strategies to date. Recognizing that the majority of...
ASCO and Ontario Health Publish Joint Update on Guideline for Targeted Therapy in NSCLC With Driver Alterations
ASCO and Ontario Health (Cancer Care Ontario) have jointly published an update1 to the 2017 ASCO guideline2 regarding systemic therapy recommendations for stage IV non–small cell lung cancer (NSCLC) with driver alterations. Guideline Co-Chair Nasser H. Hanna, MD, of the Indiana University Simon...
New Savings on HealthCare.gov Follow COVID Relief Package
As of April 1, additional savings may be available for new and current consumers who purchase health insurance on HealthCare.gov following passage of the American Rescue Plan. The Centers for Medicare & Medicaid Services (CMS) also extended access to the Special Enrollment Period (SEP) for the...
ASCO Answers Guide: Cancer Survivorship
As patients finish active treatment, they often wonder: “What happens next?” ASCO Answers: Cancer Survivorship assists in answering this often-difficult question by helping patients better understand survivorship, including its psychological, physical, sexual, reproductive, financial, and...
Fostering a Global Community of Early-Career Oncologists, Virtually
In a typical year, the new participants in ASCO and Conquer Cancer’s International Development and Education Awards (IDEA) and International Development and Education Awards–Palliative Care (IDEA-PC) program would arrive at the McCormick Place Convention Center just ahead of the ASCO Annual...
What You Need to Know About Cancer and the Coronavirus
As a three-time breast cancer survivor, when the COVID-19 pandemic hit the United States this past January, I knew I had to do everything I could to avoid getting the virus. A host of lingering side effects from my surgeries, chemotherapy, and radiation treatments have left me with cardiovascular...
Margetuximab-cmkb: A Novel Agent Overshadowed by an Abundance of Options in HER2-Positive Breast Cancer
It is incredible to reflect upon the scientific advances in the treatment of HER2-positive breast cancer over the past 23 years. Once considered the worst subtype of breast cancer, HER2-positive disease is now associated with the best long-term outcomes in this age of targeted treatments. With a...
UPMC Hillman Names New Hematology Oncology Chief
Taofeek K. Owonikoko, MD, PhD, will join the University of Pittsburgh Medical Center (UMPC) Hillman Cancer Center and Department of Medicine as Chief of the Division of Hematology/Oncology. A physician-scientist board-certified in medical oncology, hematology, and internal medicine, Dr. Owonikoko...
Randall F. Holcombe, MD, MBA, Named Director of UVM Cancer Center and Chief of Hematology and Oncology
The Robert Larner, MD, College of Medicine at The University of Vermont (UVM), in collaboration with the UVM Health Network and the UVM Medical Center, has announced that Randall F. Holcombe, MD, MBA, has been appointed Director of the UVM Cancer Center and Chief of the Division of Hematology and...
COVID-19 Pandemic Underscores Shortage of Oncologists
The expected surge of patients, some with advanced cancers, wanting and needing oncology care as the COVID-19 pandemic ebbs, underscores the need for more oncologists, according to Barbara L. McAneny, MD, MACP, FASCO, cofounder and Chief Executive Officer, New Mexico Oncology Hematology...
Oncologists Launch Global Society to Improve Clinical Research, Standardize Treatment, and Improve Patient Education About Rare Genitourinary Tumors
Late this past year, a group of oncologists led by Philippe E. Spiess, MD, MS, FRCS(C), FACS, Assistant Chief of Surgical Services and Senior Member in the Department of Genitourinary Oncology at Moffitt Cancer Center and Professor in the Department of Urology at the University of South Florida;...
Surge of Patients With Advanced Cancer Expected Due to Delayed Diagnosis and Treatment During Pandemic
Pent up demand for cancer screenings, diagnostic workups, and treatments delayed or curtailed since the start of the pandemic is expected to result in a surge of patients—some with more advanced disease as a result of delays—seeking appointments with oncologists. “We are starting to see the...
Lombardi Comprehensive Cancer Center, Georgetown University Names Kieron Dunleavy, MD, to Leadership Positions in Hematology
Kieron Dunleavy, MD, was appointed Director of Hematology at the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC. He is now also Chief of the Lymphoma Program at Georgetown University. Dr. Dunleavy joined Lombardi/Georgetown earlier this year. He is former Professor...
